课题基金 / 基金详情

Oregon Clinical and Translational Research Institute

Oregon Clinical and Translational Research Institute
俄勒冈临床和转化研究所
批准号:
10693308
负责人:
David H Ellison
金额:
$967.3万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-02 至 2027-07-31

项目摘要

项目成果

David H Ellison的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Overall - Project Summary The Oregon Clinical and Translational Research Institute (OCTRI) is a mature CTSA hub that has been accelerating research at Oregon Health & Science University (OHSU) since 2006. It has a stable, yet nimble, leadership structure that has functioned efficiently during the current funding cycle to meet its goals. OCTRI benefits from the guidance of several advisory groups in evaluation and planning and will use their input to continuously improve its structure. OCTRI’s many effective programs assist investigators and trainees by providing support services and fostering novel approaches to improve health in Oregon and beyond. OCTRI will now build on these strengths, while broadening its reach, to address goals that align with the national priorities articulated by NCATS and solidify its role within the CTSA network. OCTRI has developed nationally recognized programs to build the translational workforce, and will strengthen this base to bring more diversity, while also ensuring rigorous competencies are met. OCTRI has developed a regional reputation for leading innovation and have incorporated these assets in an optional function with the Knight Cancer Institute that supports the development of new therapeutics. OCTRI has built trust and capacity in research throughout rural Oregon and will now extend these efforts to the Portland metropolitan region. OCTRI’s current optional function has amplified the patient voice in research, and it will now be integrated into the community program in order to extend its reach. OCTRI has led in the development of national informatics platforms and will now leverage those to build internal support processes throughout OHSU to democratize these resources. At the same time, OCTRI has recognized limitations with regard to data sharing and will develop a novel optional function to incorporate Fast Healthcare Interoperability Resources to translate social determinants of health across electronic systems. OCTRI has been at the forefront of innovative outcome evaluation and will fully implement the Translational Science Benefits Model. These goals will be accomplished by engaging diverse stakeholders, by partnering with OHSU investigators, community coalitions, and business enterprises, and by fostering team science. Through these efforts, OCTRI will become even more essential for OHSU, for Oregon, and for the nation.
期刊论文(319)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/jbmr.4619
发表时间: 2022-08
期刊: JOURNAL OF BONE AND MINERAL RESEARCH
影响因子: 6.2
作者: [Alajlouni, Dima A., Bliuc, Dana, Tran, Thach S., Blank, Robert D., Cawthon, Peggy M., Ensrud, Kristine E., Lane, Nancy E., Orwoll, Eric S., Cauley, Jane A., Center, Jacqueline R.]
通讯作者: Center, Jacqueline R.
DOI: 10.1002/onco.13674
发表时间: 2021-04
期刊: The oncologist
影响因子: --
作者: [George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M]
通讯作者: von Mehren M
DOI: 10.1111/jocn.16511
发表时间: 2023-07
期刊: JOURNAL OF CLINICAL NURSING
影响因子: 4.2
作者: [Christensen, Vivian, Parker, Kellee, Chan, Lai Hin Kimi, Saxton, Lauren, Cottrell, Erika]
通讯作者: Cottrell, Erika
DOI: 10.3389/fendo.2021.651211
发表时间: 2021
期刊: Frontiers in endocrinology
影响因子: 5.2
作者: [Ehrlicher SE, Stierwalt HD, Newsom SA, Robinson MM]
通讯作者: Robinson MM
183
    Core-003
    Admin-Core-001
    Oregon Clinical and Translational Research Institute Quality Assurance and Quality Control Project
    Oregon Clinical and Translational Research Institute
    国内基金
    海外基金
    Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data